<html><body>87© world health organizationwho technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, no. 953, 2009annex 2stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of active pharmaceutical ingredients and ﬁ nished pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products1</a></span></a></span>. introduction 1.1 objectives of these guidelines
 1.2  scope of these guidelines
 1.3 general principles2. guidelines 2.1 active pharmaceutical ingredient …………………  2.1.1 general
  2.1.2 stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>
  2.1.3 selection of batches
  2.1.4 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system
  2.1.5 speciﬁ cation
  2.1.6 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> frequency
  2.1.7 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions……  2.1.8 stability commitment
  2.1.9 evaluation
  2.1.10 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span>
  2.1.11 ongoing stability studies
 2.2 finished pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>
  2.2.1 general
  2.2.2 selection of batches
  2.2.3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system
  2.2.4 speciﬁ cation
  2.2.5 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> frequency
  2.2.6 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions  2.2.7 stability commitment
  2.2.8 evaluation  2.2.9 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span>
  2.2.10 in-use stability
  2.2.11 variations
  2.2.12 ongoing stability studies3. glossary
references
appendix 1long-term stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditions as identiﬁ ed by who member <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span>.appendix 2examples of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> parameters…appendix 3recommended <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span>…881. introduction1.1 objectives of these guidelinesthese guidelines seek to exemplify the core stability data <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">package</a></span> required for registration of active pharmaceutical ingredients (apis) and 
ﬁ nished pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (fpps), replacing the previous who guidelines in this area (1,2). however, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> approaches can be used when they are scientiﬁ cally justiﬁ ed. further <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> can be found in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation (ich) guidelines (3)and in thewhoguidelines on the active pharmaceutical ingredient master ﬁ le procedure (4).it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> that these guidelines should also be applied to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> that are already being <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketed</a></span></a></span>, with allowance for an appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3614">transition</a></span> 
period, e.g. upon re-registration or upon re-evaluation.1.2 scope of these guidelinesthese guidelines apply to new and existing apis and address <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> to be submitted in original and subsequent applications for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span> 
authorization of their related fpp for human use. these guidelines are not 
applicable to stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biologicals</a></span> (for details on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4635"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4636">vaccines</a></span></a></span> please 
seewho guidelines for stability evaluation of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4635"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4636">vaccines</a></span></a></span> (5)).1.3 general principlesthe purpose of stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> is to provide <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4434">evidence</a></span> of how the quality of an api or fpp varies with time under the inﬂ uence of a variety of environmental factors such as temperature, humidity and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>. the 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability programme</a></span> also includes the study of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>-related factors 
that inﬂ uence its quality, for example, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interaction</a></span> of api with excipients, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure systems and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> materials. in ﬁ xed-dose combination fpps (fdcs) the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interaction</a></span> between two or more apis also 
has to be considered.as a result of stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> a re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period for the api (in exceptional cases, e.g. for unstable apis, a shelf-life is given) or a shelf-life for the fpp 
can be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions can be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span>.various analyses have been done to identify suitable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditions for who member <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span> based on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> data and are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/667"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1745">published</a></span></a></span> in 
the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1680">literature</a></span> (6–9) on the basis of which each member <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">state</a></span> can make its <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> on long-term (real-time) stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditions. those 
member <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span> that have notiﬁ ed who of the long-term stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditions they require when requesting a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span> authorization are 
listed in appendix 1.892. guidelines2.1 active pharmaceutical ingredient2.1.1 generalinformation on the stability of the api is an integral part of the systematic approach to stability evaluation. potential attributes to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> on an api 
during stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> are listed in the examples of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> parameters 
(appendix 2).the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period or shelf-life assigned to the api by the api manufacturer should be derived from stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> data.2.1.2 stress testingstress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of the api can help identify the likely degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, 
which, in turn, can help <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> the degradation pathways and the intrinsic 
stability of the molecule and validate the stability-indicating power of the 
analytical procedures used. the nature of the stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> will <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on 
the individual api and the type of fpp involved.for an api the following approaches may be used:—when available, it is acceptable to provide the relevant data <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/667"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1745">published</a></span></a></span> in the scientiﬁ c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1680">literature</a></span> to support the identiﬁ ed degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> and pathways;—when no data are available, stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be performed.stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> may be carried out on a single batch of the api. it should include the effect of temperature (in 10 °c increments (e.g. 50 °c, 60 °c, 
etc.) above the temperature used for accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>), humidity (e.g. 75% 
relative humidity (rh) or greater) and, where appropriate, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2213">oxidation</a></span> and 
photolysis on the api. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should also evaluate the susceptibility of 
the api to hydrolysis across a justiﬁ ed range of ph values when in solution or suspension (10).<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessing</a></span> the necessity for photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be an integral part of a stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> strategy. more details can be found in other guidelines (3).results from these studies will <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> an integral part of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> provided to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> authorities.2.1.3 selection of batchesdata from stability studies on at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> three primary batches of the api 
should normally be provided. the batches should be manufactured to a 
minimum of pilot scale by the same synthesis route as <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, 
and using a method of manufacture and procedure that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6267">simulates</a></span> the ﬁ nal process to be used for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches. the overall quality of the batches 90of api placed on stability studies should be representative of the quality of the material to be made on a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> scale.for existing active substances that are known to be stable, data from at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> two primary batches should be provided.2.1.4  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure systemthe stability studies should be conducted on the api <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> 
closure system that is the same as, or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6267">simulates</a></span>, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> proposed for 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> and distribution.2.1.5  speciﬁ cationstability studies should include <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of those attributes of the api that are susceptible to change during <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> and are likely to inﬂ uence quality, safety and/or efﬁ cacy. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should cover, as appropriate, the physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> and microbiological attributes. a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guide</a></span> as to the potential 
attributes to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> in the stability studies is provided in appendix 2.validated stability-indicating analytical procedures should be applied. 
whether and to what extent replication should be performed will <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on 
the results from validation studies (11).2.1.6  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> frequencyfor long-term studies, frequency of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be sufﬁ cient to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> the stability proﬁ le of the api.for apis with a proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period or shelf-life of at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> 12 months, the frequency of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should normally be 
every three months over the ﬁ rst year, every six months over the second year, and annually thereafter throughout the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period or shelf-life.at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, a minimum of three time points, 
including the initial and ﬁ nal time points (e.g. 0, 3 and 6 months), from a six-month study is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span>. where it is expected (based on development 
experience) that results from accelerated studies are likely to approach 
signiﬁ cant change criteria, increased <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be conducted either by adding <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> at the ﬁ nal time point or by including a fourth time point in the study design. when <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition is called 
for as a result of signiﬁ cant change at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, a minimum of four time points, including the initial and ﬁ nal time points (e.g. 0, 6, 9 and 12 months), from a 12-month study is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span>.2.1.7 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditionsin general an api should be evaluated under <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions (with 
appropriate tolerances) that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> its thermal stability and, if applicable, its 91sensitivity to moisture. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions and the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/590">lengths of studies</a></span> chosen should be sufﬁ cient to cover <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> and shipment.<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition tolerances are deﬁ ned as the acceptable variations in temperature and relative humidity of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> facilities for stability studies. 
the equipment used should be capable of controlling the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions 
within the ranges deﬁ ned in these guidelines. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions should be monitored and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3871"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3873">recorded</a></span></a></span>. short-term environmental changes due to 
opening the doors of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> facility are accepted as unavoidable. the 
effect of excursions due to equipment failure should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span>, addressed 
and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> if <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1537">judged</a></span> to affect stability results. excursions that exceed the 
deﬁ ned tolerances for more than 24 hours should be described in the study <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> and their effects <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span>.the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should normally take place over a minimum of 12 months for the number of batches speciﬁ ed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.1.3 at the time of submission, and should be continued for a period of time sufﬁ cient to cover the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period or shelf-life. for existing substances that 
are known to be stable, data covering a minimum of six months may be 
submitted. additional data accumulated during the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessment</a></span> period of the 
registration application should be submitted to the authorities upon request. 
data from the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition and, if appropriate, from the 
intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition can be used to evaluate the effect of short-
term excursions outside the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions (such as might occur 
during shipping).long-term, accelerated and, where appropriate, intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions for apis are detailed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">sections</a></span> 2.1.7.1–2.1.7.3. the general 
case applies if the api is not speciﬁ cally covered by a subsequent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span>. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions can be used if justiﬁ ed.if long-term studies are conducted at 25 °c ± 2 °c/60% rh ± 5% rh and “signiﬁ cant change” occurs at any time during six months’ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should be conducted and evaluated against signiﬁ cant change criteria. in this case, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition 
should include all long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>, unless otherwise justiﬁ ed, and the initial application should include a minimum of six months’ data from a 12-month 
study at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition.“signiﬁ cant change” for an api is deﬁ ned as failure to meet its speciﬁ cation.922.1.7.1 general casestudystorage conditionminimum time period covered by data at submissionlong-terma25 °c ± 2 °c/60% rh ± 5% rh or30 °c ± 2 °c/65% rh ± 5% rh or
30 °c ± 2 °c/75% rh ± 5% rh12 months or 6 months as described in point 2.1.7 intermediateb30 °c ± 2 °c/65% rh ± 5% rh6 monthsaccelerated40 °c ± 2 °c/75% rh ± 5% rh6 months a whether long-term stability studies are performed at 25 °c ± 2 °c/60% rh ± 5% rh or 30 °c ± 2 °c/65% rh ± 5% rh or 30 °c ± 2 °c/75% rh ± 5% rh is determined by the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> condition under which the api is 
intended to be stored (see appendix 1). <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at a more severe long-term condition can be an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> to 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> condition, i.e. 25 °c/60% rh or 30 °c/65% rh.b if 30 °c ± 2 °c/65% rh ± 5% rh or 30 °c ± 2 °c/75% rh ± 5% rh is the long-term condition there is no intermediate condition.2.1.7.2 active pharmaceutical ingredients intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a refrigeratorstudystorage conditionminimum time period covered by data at submissionlong-term5 °c ± 3 °c12 monthsaccelerateda25 °c ± 2 °c/60% rh ± 5% rh or30 °c ± 2 °c/65% rh ± 5% rh or 
30 °c ± 2 °c/75% rh ± 5% rh6 months a whether accelerated stability studies are performed at 25 ± 2 °c/60% rh ± 5% rh or 30 °c ± 2 °c/65% rh ± 5% rh or 30 °c ± 2 °c/75% rh ± 5% rh is based on a risk-based evaluation. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at a more severe long-
term condition can be an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at 25 °c/60%rh or 30 °c/65%rh.data on refrigerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span> according to the evaluation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> of these guidelines, except where explicitly noted below.if signiﬁ cant change occurs between three and six months’ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period should be based 
on the data available at the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition.if signiﬁ cant change occurs within the ﬁ rst three months’ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition a discussion should be provided to address 
the effect of short-term excursions outside the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, 
e.g. during shipping or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3629">handling</a></span>. this discussion can be supported, if 
appropriate, by further <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on a single batch of the api for a period 
shorter than three months but with more frequent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> than usual. it 
is considered unnecessary to continue to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> an api for the whole six 
months when a signiﬁ cant change has occurred within the ﬁ rst three months.932.1.7.3 active pharmaceutical ingredients intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a freezerstudystorage conditionminimum time period covered by data at submissionlong-term-20 °c ± 5 °c12 monthsin the rare case of any api of non-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> origin being intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>, the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period or shelf-life should be based on the 
long-term data obtained at the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. in the absence of 
an accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition for apis intended to be stored in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>, 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on a single batch at an elevated temperature (e.g. 5 °c ± 3 °c or 25 °c 
± 2 °c or 30 °c ± 2 °c) for an appropriate time period should be conducted 
to address the effect of short-term excursions outside the proposed <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, e.g. during shipping or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3629">handling</a></span>.2.1.7.4 active pharmaceutical ingredients intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> below -20°capis intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> below -20 °c should be treated on a case-by-case 
basis.2.1.8 stability commitmentwhen the available long-term stability data on primary batches do not cover 
the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period granted at the time of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span>, a commitment 
should be made to continue the stability studies post-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> in order to 
ﬁ rmly <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period or shelf-life.where the submission includes long-term stability data on the number of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches speciﬁ ed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.1.3 covering the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period, a post-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> commitment is considered unnecessary. otherwise 
one of the following commitments should be made:if the submission includes data from stability studies on the number of •<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches speciﬁ ed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.1.3, a commitment should be made to continue these studies through the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period.
if the submission includes data from stability studies on fewer than the •number of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches speciﬁ ed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.1.3, a commitment should be made to continue these studies through the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> 
period and to place additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, to a total of at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> 
three, in long-term stability studies through the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period.
if the submission does not include stability data on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, •a commitment should be made to place the ﬁ rst two or three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches (see <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.1.3) on long-term stability studies through the 
proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period.the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> used for long-term studies for the stability commitment should be the same as that for the primary batches, unless otherwise 
scientiﬁ cally justiﬁ ed.942.1.9 evaluationthe purpose of the stability study is to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span>, based on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> a minimum of the number of batches speciﬁ ed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.1.3, unless otherwise justiﬁ ed and authorized, of the api and evaluating the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> (including, as appropriate, results of the physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> and 
microbiological <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>), a re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period applicable to all future batches of the 
api manufactured under similar circumstances. the degree of variability of 
individual batches affects the conﬁ dence that a future <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batch will remain within speciﬁ cation throughout the assigned re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period.the data may show so little degradation and so little variability that it is apparent from looking at them that the requested re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period will be 
granted. under these circumstances it is normally unnecessary to go through 
the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis; providing a justiﬁ cation for the omission should be sufﬁ cient.an approach for analysing the data on a quantitative attribute that is expected to change with time is to determine the time at which the 95% one-sided 
conﬁ dence limit for the mean curve intersects the acceptance criterion. if analysis shows that the batch-to-batch variability is small, it is advantageous 
to combine the data into one overall estimate. this can be done by ﬁ rst applying appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> (e.g. p values for level of signiﬁ cance of rejection of more than 0.25) to the slopes of the regression lines and zero 
time intercepts for the individual batches. if it is inappropriate to combine 
data from several batches, the overall re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period should be based on 
the minimum time a batch can be expected to remain within acceptance 
criteria.the nature of any degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> will determine whether the data should be transformed for linear regression analysis. usually the 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> can be represented by a linear, quadratic or cubic function on 
an arithmetic or logarithmic scale. as far as possible, the choice of model 
should be justiﬁ ed by a physical and/or chemical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">rationale</a></span> and should also take into <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> the amount of available data (parsimony principle to 
ensure a robust prediction). <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1895"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> methods</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/735">employed</a></span> to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> 
the goodness of ﬁ t of the data on all batches and combined batches (where appropriate) to the assumed degradation line or curve.limited extrapolation of the long-term data from the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition beyond the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> range to extend the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period can be 
undertaken if justiﬁ ed. this justiﬁ cation should be based on what is known about the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1848">mechanism</a></span> of degradation, the results of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> under accelerated 
conditions, the goodness of ﬁ t of any <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1835">mathematical</a></span> model, batch size and existence of supporting stability data. however, this extrapolation assumes 
that the same degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> will continue to apply beyond the 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> data.95any evaluation should cover not only the assay but also the levels of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> and other appropriate attributes. where appropriate, 
attention should be paid to reviewing the adequacy of evaluation linked to 
fpp stability and degradation “behaviour” during the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>.2.1.10 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labellinga</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5422">display</a></span> on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> based on 
the stability evaluation of the api. where applicable speciﬁ c instructions should be provided, particularly for apis that cannot tolerate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezing</a></span> or 
excursions in temperature. terms such as “ambient conditions” or “room 
temperature” should be avoided.the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> for use if supported by the stability studies are provided in appendix 3.a re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period should be derived from the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span>, and a re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> date should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5422">displayed</a></span> on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> if appropriate.2.1.11 ongoing stability studiesthe stability of the api should be monitored according to a continuous 
and appropriate programme that will permit the detection of any stability 
issue (e.g. changes in levels of degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>). the purpose of the 
ongoing <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability programme</a></span> is to monitor the api and to determine that 
the api remains, and can be expected to remain, within speciﬁ cations under the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions indicated on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span>, within the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period in all 
future batches.the ongoing <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability programme</a></span> should be described in a written <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> and the results presented in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>.the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> for an ongoing <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability programme</a></span> should extend to the end of the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period and shelf-life and should include, but not be limited to, 
the following parameters:—number of batch(es) and different batch sizes, if applicable;—relevant physical, chemical, microbiological and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> 
methods;—acceptance criteria;—reference to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> methods;—description of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system(s);—<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> frequency;—description of the conditions of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standardized</a></span> conditions for 
long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> as described in these guidelines, and consistent with 
the api <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span>, should be used); and—other applicable parameters speciﬁ c to the api.96at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> one <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batch per year of api (unless none is produced during that year) should be added to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability monitoring programme</a></span> 
and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> annually to conﬁ rm the stability (12). in certain situations additional batches should be included in the ongoing <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability programme</a></span>. 
for example, an ongoing stability study should be conducted after any 
signiﬁ cant change or signiﬁ cant deviation to the synthetic route, process or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system which may have an impact upon the stability of 
the api (13).out-of-speciﬁ cation results or signiﬁ cant atypical trends should be investigated. any conﬁ rmed signiﬁ cant change, out-of-speciﬁ cation result, or signiﬁ cant atypical trend should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> immediately to the relevant ﬁ nished <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> manufacturer. the possible impact on batches on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">market</a></span></a></span> should be 
considered in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span> with the relevant ﬁ nished <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> manufacturers and the competent authorities.a summary of all the data generated, including any interim conclusions on 
the programme, should be written and maintained. this summary should be 
subjected to periodic review.2.2 finished pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product2</a></span></a></span>.2.1 generalthe design of the stability studies for the fpp should be based on knowledge 
of the behaviour and properties of the api, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> from stability 
studies on the api and on experience gained from preformulation studies 
and investigational fpps.2.2.2 selection of batchesdata from stability studies should be provided on at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> three primary 
batches of the fpp. the primary batches should be of the same formulation 
and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system as proposed for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>. 
the manufacturing process used for primary batches should <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6267">simulate</a></span> that 
to be applied to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches and should provide <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> of the same 
quality and meeting the same speciﬁ cation as that intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>. in the case of conventional dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> with apis that are known to be 
stable, data from at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> two primary batches should be provided.two of the three batches should be at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> pilot-scale batches and the third one can be smaller, if justiﬁ ed. where possible, batches of the fpp should be manufactured using different batches of the api(s).stability studies should be performed on each individual strength, dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> type and size of the fpp unless bracketing or matrixing 
is applied.972.2.3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure systemstability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be conducted on the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system proposed for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>. any available studies 
carried out on the fpp outside its immediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> or in other <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> 
materials can <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> a useful part of the stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> or 
can be considered as supporting <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span>, respectively.2.2.4 speciﬁ cationstability studies should include <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of those attributes of the fpp that are susceptible to change during <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> and are likely to inﬂ uence quality, safety, and/or efﬁ cacy. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should cover, as appropriate, the physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> and microbiological attributes, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> content 
(e.g. antioxidant or antimicrobial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span>) and functionality <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> (e.g. 
for a dose delivery system). examples of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> parameters in the stability 
studies are listed in appendix 2. analytical procedures should be fully 
validated and stability-indicating. whether and to what extent replication 
should be performed will <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on the results of validation studies.shelf-life acceptance criteria should be derived from consideration of all available stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span>. it may be appropriate to have justiﬁ able differences between the shelf-life and release acceptance criteria based on 
the stability evaluation and the changes <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span>. any differences 
between the release and shelf-life acceptance criteria for antimicrobial 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> content should be supported by a validated correlation of 
chemical content and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> effectiveness demonstrated during 
development of the pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> with the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> in its ﬁ nal formulation (except for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> concentration) intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>. 
a single primary stability batch of the fpp should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> for effectiveness 
of the antimicrobial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> (in addition to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> content) at the 
proposed shelf-life for veriﬁ cation purposes, regardless of whether there is a difference between the release and shelf-life acceptance criteria for 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> content.2.2.5 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> frequencyfor long-term studies, frequency of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be sufﬁ cient to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> the stability proﬁ le of the fpp.for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> with a proposed shelf-life of at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> 12 months, the frequency of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should normally be every 
three months over the ﬁ rst year, every six months over the second year and annually thereafter throughout the proposed shelf-life.at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, a minimum of three time points, including the initial and ﬁ nal time points (e.g. 0, 3 and 6 months), from a six-month study is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span>. where an expectation (based on 98development experience) exists that results from accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> are likely to approach signiﬁ cant change criteria, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be increased either by adding <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> at the ﬁ nal time point or by including a fourth time point in the study design.when <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition is called for as a result of signiﬁ cant change at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, a minimum of four time points, including the initial and ﬁ nal time points (e.g. 0, 6, 9 and 12 months), from a 12-month study is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span>.reduced designs, i.e. matrixing or bracketing, where the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> frequency is reduced or certain factor combinations are not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at all, can be applied 
if justiﬁ ed (3).2.2.6 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditionsin general an fpp should be evaluated under <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions with speciﬁ ed tolerances that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> its thermal stability and, if applicable, its sensitivity to moisture or potential for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span>. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions 
and the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/590">lengths of studies</a></span> chosen should be sufﬁ cient to cover <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span>, shipment and subsequent use with due regard to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> conditions in 
which the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is intended to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketed</a></span></a></span>.photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>, which is an integral part of stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>, should be conducted on at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> one primary batch of the fpp if appropriate. more 
details can be found in other guidelines (3).the orientation of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> during <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span>, i.e. upright versus inverted, may need to be included in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> where contact of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> with 
the closure system may be expected to affect the stability of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contained</a></span>, or where there has been a change in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure 
system.<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition tolerances are usually deﬁ ned as the acceptable variations in temperature and relative humidity of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> facilities for stability studies. 
the equipment used should be capable of controlling the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions 
within the ranges deﬁ ned in these guidelines. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions should be monitored and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3871"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3873">recorded</a></span></a></span>. short-term environmental changes due to 
opening of the doors of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> facility are accepted as unavoidable. the 
effect of excursions due to equipment failure should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span>, addressed 
and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> if <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1537">judged</a></span> to affect stability results. excursions that exceed the 
deﬁ ned tolerances for more than 24 hours should be described in the study <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> and their effects <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span>.the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should cover a minimum of six or 12 months at the time of submission and should be continued for a period of time sufﬁ cient to cover the proposed shelf-life. for an fpp <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containing</a></span> an api that is known 
to be stable and where no signiﬁ cant change is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> in the fpp stability 99studies at accelerated and long-term conditions for at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> 6 months data covering a minimum of six months should be submitted.additional data accumulated during the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessment</a></span> period of the registration application should be submitted to the authorities if requested. data from the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition and from the intermediate conditions, where appropriate, can be used to evaluate the effect of short-term excursions 
outside the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions (such as might occur during shipping).long-term, accelerated and, where appropriate, intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions for fpps are detailed in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">sections</a></span> below. the general case 
applies if the fpp is not speciﬁ cally covered by a subsequent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> (2.1.7.1). <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions can be used if justiﬁ ed.2.2.6.1 general casestudystorage conditionminimum time period covered by data at submissionlong-terma25 °c ± 2 °c/60% rh ± 5% rh or30 °c ± 2 °c/65% rh ± 5% rh or 
30 °c ± 2 °c/75% rh ± 5% rh 12 months or 6 months as referred to in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.2.6intermediateb30 °c ± 2 °c/65% rh ± 5% rh6 monthsaccelerated40 °c ± 2 °c/75% rh ± 5% rh6 months a whether long-term stability studies are performed at 25 °c ± 2 °c/60% rh ± 5% rh or 30 °c ± 2 °c/65% rh ± 5% rh or 30 °c ± 2 °c/75% rh ± 5% rh is determined by the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zone</a></span> in which the fpp is intended to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketed</a></span></a></span> . <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at a more severe long-term condition can be an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> at 25 °c/60% rh or 30 °c/65% rh.b if 30 °c ± 2 °c/65% rh ± 5% rh or 30 °c ± 2 °c/75% rh ± 5% rh is the long-term condition, there is no intermediate condition.if long-term studies are conducted at 25 °c ± 2 °c/60% rh ± 5% rh and “signiﬁ cant change” occurs at any time during six months’ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> 
condition should be conducted and evaluated against signiﬁ cant change criteria. in this case the initial application should include a minimum of six 
months’ data from a 12-month study at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition.in general “signiﬁ cant change” for an fpp is deﬁ ned as:a change from the initial content of api(s) of 5% or more detected by •assay, or failure to meet the acceptance criteria for potency when using 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1304">immunological</a></span> procedures. (note: other values may be applied, if justiﬁ ed, to certain <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, such as multivitamins and herbal preparations.)
any degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> exceeding its acceptance criterion.•failure to meet the acceptance criteria for appearance, physical attributes •and functionality <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> (e.g. colour, phase separation, resuspendability, 100caking, hardness, dose delivery per actuation). however, some changes in physical attributes (e.g. softening of suppositories, melting of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/301">creams</a></span>, 
partial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3">adhesion</a></span> for transdermal <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>) may be expected under 
accelerated conditions.also, as appropriate for the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span>:failure to meet the acceptance criterion for ph;•orfailure to meet the acceptance criteria for dissolution for 12 dosage units.•2.2.6.2 fpps <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in impermeable containersparameters required to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6004">classify</a></span> the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> materials as permeable or impermeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on the characteristics of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> material, 
such as thickness and permeability coefﬁ cient. the suitability of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> material used for a particular <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is determined by its 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> characteristics. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> generally considered to be moisture-
impermeable include <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4676">glass</a></span> ampoules.sensitivity to moisture or potential for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> is not a concern for fpps <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in impermeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> that provide a permanent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4819">barrier</a></span> to 
passage of moisture or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span>. thus stability studies for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> stored in 
impermeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> can be conducted under any controlled or ambient 
relative humidity condition.2.2.6.3 fpps <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in semi-permeable containersaqueous-based <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> should 
be evaluated for potential <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> in addition to physical, chemical, 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> and microbiological stability. this evaluation can be carried out 
under conditions of low relative humidity, as discussed below. ultimately it 
should be demonstrated that aqueous-based fpps stored in semi-permeable 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> could withstand environments with low relative humidity.other comparable approaches can be developed and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> for non-aqueous, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span>-based <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>.studystorage conditionminimum time period covered by data at submissionlong-terma25 °c ± 2 °c/40% rh ± 5% rh or30 °c ± 2 °c/35% rh ± 5% rh12 monthsintermediate30 °c ± 2 °c/65% rh ± 5% rh6 monthsaccelerated 40 °c ± 2 °c/not more than(nmt) 25% rh6 months a whether long-term stability studies are performed at 25 °c ± 2 °c/40% rh ± 5% rh or 30 °c ± 2 °c/35% rh ± 5% rh is determined by the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> condition under which the fpp is intended to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketed</a></span></a></span>. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at 30 °c/35% rh can be an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition at 25 °c/40% rh.101products meeting either of the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions and the accelerated conditions, as speciﬁ ed in the table above, have demonstrated the integrity of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> in semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span>. a signiﬁ cant change in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> alone at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition does not 
necessitate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. however, data 
should be provided to demonstrate that the pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> would 
not have signiﬁ cant <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> throughout the proposed shelf-life if stored at 25 °c/40% rh or 30 °c/35% rh.for long-term studies conducted at 25 °c ± 2 °c/40% rh ± 5% rh, that fail the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> with regard to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> and any other parameters, 
additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the “intermediate” <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition should be 
performed as described under the general case to evaluate the temperature 
effect at 30 °c.a 5% <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> from its initial value is considered a signiﬁ cant change for a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in a semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> after an equivalent of 
three months’ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> at 40 °c not more than (nmt) 25% rh. however, for 
small <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> (1 ml or less) or unit-dose <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> of 5% or 
more after an equivalent of three months’ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> at 40 °c/nmt 25% rh 
may be appropriate, if justiﬁ ed.an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> approach to studies at the low relative humidity as <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> in the table above (for either long-term or accelerated 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>) is to perform the stability studies under higher relative humidity 
and deriving the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> at the low relative humidity through calculation. 
this can be achieved by experimentally determining the permeation 
coefﬁ cient for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system or, as shown in the example below, using the calculated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratio</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rates between the two 
humidity conditions at the same temperature. the permeation coefﬁ cient for a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system can be experimentally determined by using 
the worst-case scenario (e.g. the most diluted of a series of concentrations) 
for the proposed fpp.example of an approach for determining <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">lossfor</a></span> a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> in a given <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size and ﬁ ll, an appropriate approach for deriving the rate of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> at the low relative 
humidity is to multiply the rate of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> measured at an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> 
relative humidity at the same temperature, by a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratio</a></span> shown 
in the table below. a linear <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rate at the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> relative humidity 
over the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> period should be demonstrated.for example, at a given temperature, e.g. 40 °c, the calculated rate of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> during <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> at nmt 25% rh is the rate of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> measured at 
75% rh multiplied by 3.0, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/242">corresponding</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratio</a></span>.102low-humiditytesting conditionsalternativetesting conditionratio of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rates calculation25 °c/40% rh25 °c/60% rh1.5(100-40)/(100-60)30 °c/35% rh30 °c/65% rh1.9(100-35)/(100-65)
30 °c/35% rh30 °c/75% rh2.6(100-35)/(100-75)40 °c/nmt 25% rh40 °c/75% rh3.0(100-25)/(100-75)valid <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> rate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratios</a></span> at relative humidity conditions other than those shown in the table above can also be used.2.2.6.4 fpps intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a refrigeratorstudystorage conditionminimum time period covered by data at submissionlong-term5 °c ± 3 °c 12 monthsaccelerateda25 °c ± 2 °c/60% rh ± 5% rh or30 °c ± 2 °c/65% rh ± 5% rh or
30 °c ± 2 °c/75% rh ± 5% rh6 months a whether accelerated stability studies are performed at 25 ± 2 °c/60% rh ± 5% rh or 30 °c ± 2 °c/65% rh ± 5% rh or 30 °c ± 2 °c/75% rh ± 5% rh is based on a risk-based evaluation. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at a more severe 
accelerated condition can be an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition at 25 °c/60% rh or 30 °c/65% rh.if the fpp is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in a semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span>, appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> should be provided to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assess</a></span> the extent of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span>.data from refrigerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span> according to the evaluation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> of these guidelines, except where explicitly noted below.if signiﬁ cant change occurs between three and six months’ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, the proposed shelf-life should be based on 
the data available from the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition.if signiﬁ cant change occurs within the ﬁ rst three months’ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, a discussion should be provided to address the 
effect of short-term excursions outside the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, e.g. during 
shipment and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3629">handling</a></span>. this discussion can be supported, if appropriate, by 
further <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on a single batch of the fpp for a period shorter than three 
months but with more frequent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> than usual. it is considered unnecessary 
to continue to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> throughout six months when a signiﬁ cant change has occurred within the ﬁ rst three months of accelerated studies at the speciﬁ c condition chosen in accordance with the risk analysis.1032.2.6.5 fpps intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a freezerstudystorage conditionminimum time period coveredby data at submissionlong-term–20 °c ± 5 °c12 monthsfor fpps intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>, the shelf-life should be based on the long-term data obtained at the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition. in the absence of an accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition for fpps intended to be stored 
in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on a single batch at an elevated temperature (e.g. 5 °c 
± 3 °c or 25 °c ± 2 °c or 30 °c ± 2 °c) for an appropriate time period 
should be conducted to address the effect of short-term excursions outside 
the proposed <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition.2.2.6.6 fpps intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> below -20 °cfpps intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> at temperatures below -20 °c should be treated on a case-by-case basis.2.2.7 stability commitmentwhen the available long-term stability data on primary batches do not cover 
the proposed shelf-life granted at the time of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span>, a commitment should 
be made to continue the stability studies post-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> to ﬁ rmly <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> the shelf-life.where the submission includes long-term stability data from the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches as speciﬁ ed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.2.2 covering the proposed shelf-life, a post-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> commitment is considered unnecessary. otherwise, one of the 
following commitments should be made:if the submission includes data from stability studies on at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> the number •of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches speciﬁ ed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.2.2, a commitment should be made to continue the long-term studies throughout the proposed shelf-
life and the accelerated studies for six months.
if the submission includes data from stability studies on fewer than the •number of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches speciﬁ ed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.2.2, a commitment should be made to continue the long-term studies throughout the proposed 
shelf-life and the accelerated studies for six months, and to place 
additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, to a total of at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> three, on long-term 
stability studies throughout the proposed shelf-life and on accelerated 
studies for six months.if the submission does not include stability data on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches, •a commitment should be made to place the ﬁ rst two or three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches (see <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.2.2) on long-term stability studies throughout the 
proposed shelf-life and on accelerated studies for six months.104the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> used for studies on commitment batches should be the same as that for the primary batches, unless otherwise scientiﬁ cally justiﬁ ed.2.2.8 evaluationa systematic approach should be adopted to the presentation and evaluation of the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span>, which should include, as appropriate, results 
from the physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> and microbiological <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>, including 
particular attributes of the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> (for example, dissolution rate for 
solid oral dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span>).the purpose of the stability study is to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span>, based on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> a minimum number of batches of the fpp as speciﬁ ed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.2.2, a shelf-life and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> instructions applicable to all future batches of the fpp 
manufactured under similar circumstances. the degree of variability of 
individual batches affects the conﬁ dence that a future <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batch will remain within speciﬁ cation throughout its shelf-life.where the data show so little degradation and so little variability that it is apparent from looking at the data that the requested shelf-life will be 
granted, it is normally unnecessary to go through the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis. 
however, a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3446">provisional</a></span> shelf-life of 24 months may be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> provided 
the following conditions are satisﬁ ed:the api is known to be stable (not easily degradable).•stability studies, as outlined above in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.1.11, have been performed •and no signiﬁ cant changes have been <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span>.supporting data indicate that similar formulations have been assigned a •shelf-life of 24 months or more.
the manufacturer will continue to conduct long-term studies until the •proposed shelf-life has been covered, and the results obtained will be 
submitted to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2033"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2034"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3521">national</a></span></a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1852">medicines</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> authority.an approach for analysing the data on a quantitative attribute that is expected 
to change with time is to determine the time at which the 95% one-sided 
conﬁ dence limit for the mean curve intersects the acceptance criterion. if analysis shows that the batch-to-batch variability is small, it is advantageous 
to combine the data into one overall estimate. this can be done by ﬁ rst applying appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> (e.g. p values for level of signiﬁ cance of rejection of more than 0.25) to the slopes of the regression lines and zero time 
intercepts for the individual batches. if it is inappropriate to combine data 
from several batches, the overall shelf-life should be based on the minimum 
time a batch can be expected to remain within acceptance criteria.the nature of any degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> will determine whether the 
data should be transformed for linear regression analysis. usually the 105relationship can be represented by a linear, quadratic or cubic function on an arithmetic or logarithmic scale. as far as possible, the choice of model should be justiﬁ ed by a physical and/or chemical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">rationale</a></span> and should also take into <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> the amount of available data (parsimony principle to 
ensure a robust prediction).<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1895"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> methods</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/735">employed</a></span> to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> the goodness of ﬁ t of the data on all batches and combined batches (where appropriate) to the assumed 
degradation line or curve.limited extrapolation of the long-term data from the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition beyond the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> range to extend the shelf-life can be 
undertaken, if justiﬁ ed. this justiﬁ cation should be based on what is known about the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1848">mechanism</a></span> of degradation, the results of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> under accelerated 
conditions, the goodness of ﬁ t of any <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1835">mathematical</a></span> model, batch size and the existence of supporting stability data. however, this extrapolation assumes 
that the same degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> will continue to apply beyond the 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> data.any evaluation should consider not only the assay but also the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> and other appropriate attributes. where appropriate, attention 
should be paid to reviewing the adequacy of evaluation linked to fpp 
stability and degradation “behaviour” during the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>.2.2.9 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labellinga</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> based on the stability 
evaluation of the fpp. where applicable, speciﬁ c instructions should be provided, particularly for fpps that cannot tolerate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezing</a></span>. terms such as 
“ambient conditions” or “room temperature” must be avoided.there should be a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">direct</a></span> link between the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span> on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> and the demonstrated stability of the fpp. an expiry date should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5422">displayed</a></span> 
on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span>.the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> for use, if supported by the stability studies, are provided in appendix 3.in principle, fpps should be packed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> that ensure stability and protect the fpp from deterioration. a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span> should not be used 
to compensate for inadequate or inferior <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span>. additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> could be used in cases where the results of the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> 
demonstrate limiting factors (see also appendix 3).2.2.10 in-use stabilitythe purpose of in-use stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> is to provide <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> for the 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> on the preparation, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions and utilization period of 106multidose <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> after opening, reconstitution or dilution of a solution, e.g. an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1997">antibiotic</a></span> injection <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2292">supplied</a></span> as a powder for reconstitution.as far as possible the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> should be designed to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6267">simulate</a></span> the use of the fpp in practice, taking into consideration the ﬁ lling volume of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> and any dilution or reconstitution before use. at intervals comparable to those 
which occur in practice appropriate quantities should be removed by the 
withdrawal methods normally used and described in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1680">literature</a></span>.the physical, chemical and microbial properties of the fpp susceptible to 
change during <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> should be determined over the period of the proposed 
in-use shelf-life. if possible, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be performed at intermediate time 
points and at the end of the proposed in-use shelf-life on the ﬁ nal amount of the fpp remaining in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span>. speciﬁ c parameters, e.g. for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1672">liquids</a></span> and semi-solids, preservatives, per content and effectiveness, need to be studied.a minimum of two batches, at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> pilot-scale batches, should be subjected 
to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span>. at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> one of these batches should be chosen towards the end 
of its shelf-life. if such results are not available, one batch should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> 
at the ﬁ nal point of the submitted stability studies.this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be performed on the reconstituted or diluted fpp throughout the proposed in-use period on primary batches as part of the 
stability studies at the initial and ﬁ nal time points and, if full shelf-life, long-term data are not available before submission, at 12 months or the last 
time point at which data will be available.in general this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> need not be repeated on commitment batches (see 2.2.10).2.2.11 variationsonce the fpp has been registered, additional stability studies are required 
whenever variations that may affect the stability of the api or fpp are made, 
such as major variations (13).the following are examples of such changes:—change in the manufacturing process;—change in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3122">composition</a></span> of the fpp;—change of the immediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span>;—change in the manufacturing process of an api.in all cases of variations, the applicant should <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1488">investigate</a></span> whether the intended change will or will not have an impact on the quality characteristics 
of apis and/or fpps and consequently on their stability.the scope and design of the stability studies for variations and changes are based on the knowledge and experience acquired on apis and fpps.107the results of these stability studies should be communicated to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> authorities concerned (14).2.2.12 ongoing stability studiesafter a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span> authorization has been granted, the stability of the fpp should be monitored according to a continuous appropriate programme 
that will permit the detection of any stability issue (e.g. changes in levels 
of impurities or dissolution proﬁ le) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2944">associated</a></span> with the formulation in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system in which it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketed</a></span></a></span>. the purpose of the 
ongoing <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability programme</a></span> is to monitor the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> over its shelf-life 
and to determine that the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> remains, and can be expected to remain, 
within speciﬁ cations under the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span>.this mainly applies to the fpp in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system in which it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2292">supplied</a></span>, but consideration should also be given to inclusion in the programme 
of bulk <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. for example, when the bulk <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is stored for a long period 
before being <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> and/or shipped from a manufacturing site to a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> 
site, the impact on the stability of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be evaluated 
and studied. generally this would <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> part of development studies, but where 
this need has not been foreseen, inclusion of a one-off study in the ongoing 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability programme</a></span> could provide the necessary data. similar considerations 
could apply to intermediates that are stored and used over prolonged periods.the ongoing <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability programme</a></span> should be described in a written <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> 
and results formalized as a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>.the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> for an ongoing <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability programme</a></span> should extend to the end of the shelf-life period and should include, but not be limited to, the 
following parameters:—number of batch(es) per strength and different batch sizes, if applicable. 
the batch size should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3871"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3873">recorded</a></span></a></span>, if different batch sizes are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/735">employed</a></span>;—relevant physical, chemical, microbiological and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> 
methods;—acceptance criteria;—reference to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> methods;—description of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system(s);—<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> frequency;—description of the conditions of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standardized</a></span> conditions for 
long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> as described in these guidelines, and consistent with 
the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span>, should be used); and—other applicable parameters speciﬁ c to the fpp.the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> for the ongoing <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability programme</a></span> can be different from that of the initial long-term stability study as submitted in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span> 
authorization dossier provided that this is justiﬁ ed and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">documented</a></span></a></span> in the 108protocol (for example, the frequency of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>, or when updating to meet revised recommendations).the number of batches and frequency of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should provide sufﬁ cient data to allow for trend analysis. unless otherwise justiﬁ ed, at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> one batch per year of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> manufactured in every strength and every primary <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> 
type, if relevant, should be included in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability programme</a></span> (unless none 
is produced during that year). the principle of bracketing and matrixing 
designs may be applied if scientiﬁ cally justiﬁ ed in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> (15).in certain situations additional batches should be included in the ongoing <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6340">stability programme</a></span>. for example, an ongoing stability study should be 
conducted after any signiﬁ cant change or signiﬁ cant deviation to the process or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system. any reworking, reprocessing or recovery 
operation should also be considered for inclusion (13).out-of-speciﬁ cation results or signiﬁ cant atypical trends should be investigated. any conﬁ rmed signiﬁ cant change, out-of-speciﬁ cation result, or signiﬁ cant atypical trend should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> immediately to the relevant competent authorities. the possible impact on batches on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">market</a></span></a></span> should 
be considered in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span> with the relevant competent authorities.a summary of all the data generated, including any interim conclusions on the programme, should be written and maintained. this summary should be 
subjected to periodic review.3. glossarythe deﬁ nitions provided below apply to the words and phrases used in these guidelines. although an effort has been made to use <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standard</a></span> deﬁ nitions as far as possible, they may have different meanings in other contexts and 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">documents</a></span></a></span>. the following deﬁ nitions are provided to facilitate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1482">interpretation</a></span> of the guidelines. the deﬁ nitions are consistent with those <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/667"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1745">published</a></span></a></span> in other who quality assurance guidelines. the quality assurance of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1852">medicines</a></span> 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4441">terminology</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4821">database</a></span> was <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> in august 2005 and includes the 
deﬁ nitions of terms related to quality assurance of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1852">medicines</a></span>. this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4821">database</a></span> is intended to help harmonize <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4441">terminology</a></span> and to avoid misunderstandings that 
may result from the different terms and their interpretations used in various 
who publications. the main publications used as a source of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> 
to create the quality assurance of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1852">medicines</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4441">terminology</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4821">database</a></span> are the 
quality assurance guidelines included in the 36th–42nd <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reports</a></span> of the who 
expert committee on speciﬁ cations for pharmaceutical preparations.accelerated testingstudies designed to increase the rate of chemical degradation and physical change of an api or fpp by using exaggerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions as part of 109the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> programme. the data thus obtained, in addition to those derived from long-term stability studies, may be used to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assess</a></span> longer-
term chemical effects under non-accelerated conditions and to evaluate the 
impact of short-term excursions outside the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions, as might occur during shipping. the results of accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> studies are not always predictive of physical changes.active pharmaceutical ingredient (api)any substance or mixture of substances intended to be used in the 
manufacture of a pharmaceutical dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> and that, when so used, 
becomes an active ingredient of that pharmaceutical dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span>. such 
substances are intended to furnish <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2367">pharmacological</a></span> activity or other <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">direct</a></span> 
effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.batcha deﬁ ned quantity of starting material, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> material or ﬁ nished pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> (fpp) processed in a single process or series of 
processes so that it is expected to be homogeneous. it may sometimes be 
necessary to divide a batch into a number of sub-batches, which are later 
brought together to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> a ﬁ nal homogeneous batch. in the case of terminal sterilization, the batch size is determined by the capacity of the autoclave. 
in continuous manufacture, the batch must <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/242">correspond</a></span> to a deﬁ ned fraction of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span>, characterized by its intended homogeneity. the batch 
size can be deﬁ ned either as a ﬁ xed quantity or as the amount produced in a ﬁ xed time interval.bracketingthe design of a stability schedule such that only <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> at the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span> of certain design factors, e.g. strength and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">package</a></span> size, are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at all 
time points as in a full design. the design assumes that the stability of any 
intermediate levels is represented by the stability of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>. 
where a range of strengths is to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>, bracketing is applicable if the 
strengths are identical or very closely related in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3122">composition</a></span> (e.g. for a 
tablet range made with different compression weights of a similar basic 
granulation, or a capsule range made by ﬁ lling different plug ﬁ ll weights of the same basic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3122">composition</a></span> into different size capsule shells). bracketing 
can be applied to different <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes or different ﬁ lls in the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system.<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zonethe zones</a></span> into which the world is divided based on the prevailing annual 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> conditions (see appendix 1).110commitment batchesproduction batches of an api or fpp for which the stability studies are initiated or completed post-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> through a commitment made in a 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> application.<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure systemthe sum of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> components that together <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contains</a></span> and protects the 
dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span>. this includes primary <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> components and secondary 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> components, if the latter are intended to provide additional 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2844">protection</a></span> to the fpp. a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> system is equivalent to a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> 
closure system.dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formthe</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> of the fpp, e.g. tablet, capsule, elixir or suppository.excipienta substance or compound, other than the api and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> materials, that 
is intended or designated to be used in the manufacture of a fpp.expiry datethe date given on the individual <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> (usually on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span>) of a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> 
up to and including which the api and fpp are expected to remain within speciﬁ cations, if stored correctly. it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> for each batch by adding the shelf-life to the date of manufacture.ﬁ nished pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> (fpp)a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> that has undergone all stages of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span>, including <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> 
in its ﬁ nal <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span>. an fpp may <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contain</a></span> one or more apis.impermeable containerscontainers that provide a permanent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4819">barrier</a></span> to the passage of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1139">gases</a></span> or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>, e.g. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1870"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6406">sealed</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1446">aluminium</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4575">tubes</a></span> for semisolids, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1870"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6406">sealed</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4676">glass</a></span> ampoules 
for solutions and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1446">aluminium</a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1446">aluminium</a></span> blisters for solid dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span>.in useseeutilization periodlong-term stability studiesexperiments on the physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span>, biopharmaceutical and microbiological characteristics of an api or fpp, during and beyond 
the expected shelf-life and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> periods of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> under the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> 
conditions expected in the intended <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">market</a></span></a></span>. the results are used to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> 
the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period or the shelf-life, to conﬁ rm the projected re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period and shelf-life, and to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommend</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions.111matrixingthe design of a stability schedule such that a selected subset of the total number of possible <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> for all factor combinations is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at a 
speciﬁ ed time point. at a subsequent time point, another subset of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> for all factor combinations is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>. the design assumes that the stability 
of each subset of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> represents the stability of all <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> at a 
given time point. the differences in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> for the same fpp should 
be identiﬁ ed as, for example, covering different batches, different strengths, different sizes of the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system, and, possibly in some 
cases, different <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure systems.ongoing stability studythe study carried out by the manufacturer on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batches according 
to a predetermined schedule in order to monitor, conﬁ rm and extend the projected re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period (or shelf-life) of the api, or conﬁ rm or extend the shelf-life of the fpp.pilot-scale batcha batch of an api or fpp manufactured by a procedure fully representative of and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6267">simulating</a></span> that to be applied to a full <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span>-scale batch. 
for example, for solid oral dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span>, a pilot scale is generally, at a 
minimum, one-tenth that of a full <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> scale or 100 000 tablets or capsules, whichever is the larger; unless otherwise adequately justiﬁ ed.primary batcha batch of an api or fpp used in a stability study, from which stability data are submitted in a registration application for the purpose of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> a 
re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period or shelf-life, as the case may be. a primary batch of an api 
should be at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> a pilot-scale batch. for an fpp, two of the three batches 
should be at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> pilot-scale batches, and the third batch can be smaller if it 
is representative with regard to the critical manufacturing steps. however, a primary batch may be a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batch.<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batcha batch of an api or fpp manufactured at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> scale by using <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> 
equipment in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> facility as speciﬁ ed in the application.<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3446">provisional</a></span> shelf-lifea <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3446">provisional</a></span> expiry date which is based on acceptable accelerated and available long-term data for thefpp to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketed</a></span></a></span> in the proposed 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system.release speciﬁ cationthe combination of physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span>, and microbiological 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> and acceptance criteria that determine the suitability of an api or fpp 
at the time of its release.112re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> datethe date after which an active api should be re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/925">examined</a></span> to ensure that the material is still in compliance with the speciﬁ cation and thus is still suitable for use in the manufacture of an fpp.re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> periodthe period of time during which the api is expected to remain within its 
speciﬁ cation and, therefore, can be used in the manufacture of a given fpp, provided that the api has been stored under the deﬁ ned conditions. after this period a batch of api destined for use in the manufacture of an fpp 
should be re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> for compliance with the speciﬁ cation and then used immediately. a batch of api can be re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> multiple times and a different 
portion of the batch used after each re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span>, as long as it continues to comply 
with the speciﬁ cation. for most substances known to be labile, it is more appropriate to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> a shelf-life than a re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period. the same may be 
true for certain <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1997">antibiotics</a></span>.semi-permeable containerscontainers that allow the passage of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span>, usually <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span>, while preventing 
solute <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span>. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1848">mechanism</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> transport occurs by adsorption into 
one <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> surface, diffusion through the bulk of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> material, 
and desorption from the other <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4510">surface. transport</a></span> is driven by a partial-
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2599">pressure</a></span> gradient. examples of semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> include <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1837">plastic</a></span> 
bags and semi-rigid, low-density polyethylene (ldpe) pouches for large 
volume parenterals (lvps), and ldpe ampoules, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/722">bottles</a></span> and vials.shelf-lifethe period of time during which an api or fpp, if stored correctly, is 
expected to comply with the speciﬁ cation as determined by stability studies on a number of batches of the api or fpp. the shelf-life is used to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> 
the expiry date of each batch.shelf-life speciﬁ cationthe combination of physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span>, and microbiological 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> and acceptance criteria that an fpp should meet throughout its shelf-
life. in certain exceptional cases an unstable api might have a shelf-life 
speciﬁ cation (see <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 1.3).signiﬁ cant change(see <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.2.6.1.)in general “signiﬁ cant change” for an fpp is deﬁ ned as:1. a 5% or more change in assay from its initial content of api(s), or failure to meet the acceptance criteria for potency when using <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> 
or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1304">immunological</a></span> procedures. (note:other values may be applied, 113if justiﬁ ed, to certain <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, such as multivitamins and herbal preparations.)2. any degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> exceeding its acceptance criterion.
3. failure to meet the acceptance criteria for appearance, physical attributes and functionality <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> (e.g. colour, phase separation, resuspendability, 
caking, hardness, dose delivery per actuation). however, some changes 
in physical attributes (e.g. softening of suppositories, melting of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/301">creams</a></span> 
or partial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3">adhesion</a></span> for transdermal <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>) may be expected 
under accelerated conditions.also, as appropriate for the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span>:
4. failure to meet the acceptance criterion for ph.
or
5. failure to meet the acceptance criteria for dissolution for 12 dosage units.speciﬁ cationa list of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>, references to analytical procedures, and appropriate 
acceptance criteria, which are numerical limits, ranges or other criteria for 
the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> described. it <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishes</a></span> the set of criteria to which an api or fpp 
should conform to be considered acceptable for its intended use.stability indicating methodsvalidated analytical procedures that can detect the changes with time in the 
chemical, physical or microbiological properties of the api or fpp, and that 
are speciﬁ c so that the content of the api, degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, and other components of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1476">interest</a></span> can be accurately measured without <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1436">interference</a></span>.stability studies (stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>)long-term and accelerated (and intermediate) studies undertaken on 
primary and/or commitment batches according to a prescribed stability 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> or conﬁ rm the re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period (or shelf-life) of an api or the shelf-life of an fpp.stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> (of the api)studies undertaken to elucidate the intrinsic stability of api. such <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> 
is part of the development strategy and is normally carried out under more 
severe conditions than those used for accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>.stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> (of the fpp)studies undertaken to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assess</a></span> the effect of severe conditions on the fpp. 
such studies include photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> and speciﬁ c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on certain <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (e.g. metered dose inhalers, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/301">creams</a></span>, emulsions, refrigerated 
aqueous <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1672">liquid</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>).114supporting stability datasupplementary data, such as stability data on small-scale batches, related formulations, and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> presented in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> not necessarily the 
same as those proposed for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>, and scientiﬁ c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">rationales</a></span> that support the analytical procedures, the proposed re-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period or the shelf-life and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions.utilization perioda period of time during which a reconstituted preparation of the ﬁ nished dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> in an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2179">unopened</a></span> multidose <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> can be used.references 1. guidelines for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containing</a></span> well <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> drug substances in conventional dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span>. in: who expert committee on speciﬁ cations for pharmaceutical preparations. thirty-fourth <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>. geneva, world health organization, 1996, annex 5 (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, no. 863). these guidelines were revised at the thirty-seventh and fortieth meetings of the who expert committee on speciﬁ cations for pharmaceutical preparations. in: who expert committee on speciﬁ cations for pharmaceutical preparations. thirty-seventh <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>. geneva, world health organization, 2003 (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, no. 908), p. 13 and whoexpert committee on speciﬁ cations for pharmaceutical preparations. fortieth <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>. geneva, world health organization, 2006 (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, no. 937), p. 12. 2. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regional</a></span></a></span> guidelines on stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of active substances and pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> for the who eastern mediterranean <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">region</a></span></a></span>.august 2006 (http://www.emro.who.int/edb/media/pdf/emrc5312en.pdf). 3. the following ich guidelines may be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5535">consulted</a></span></a></span> in the context of stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation. ich q1a (r2): stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (http://www.ich.org/lob/media/media419.pdf). <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation. ich q1b: photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (http://www.ich.org/lob/media/media412.pdf). <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation.ich q1c: stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> (http://www.ich.org/lob/media/media413.pdf). <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation. ich q1d: bracketing and matrixing designs for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 
(http://www.ich.org/lob/media/media414.pdf). <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation. ich q1e: evaluation for stability data(http://www.ich.org/lob/media/media415.pdf). <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation. ich q2r1): validation of analytical procedures: text and methodology (http://www.ich.org/lob/media/media417.pdf).115 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation. ich q3a: impurities in new drug substances(http://www.ich.org/lob/media/media422.pdf). <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation. ich q3b: impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (http://www.ich.org/lob/media/media421.pdf). <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation. ich q5c: stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3797">biotechnological</a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (http://www.ich.org/lob/media/media427.pdf).<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation. ich q6a: speciﬁ cations: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> procedures and acceptance criteria for new drug substances and new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>: chemical substances (http://www.ich.org/lob/media/media430.pdf). <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation.ich q6b: speciﬁ cations: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> procedures and acceptance criteria for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3797">biotechnological</a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (http://www.ich.org/lob/media/media432.pdf). further <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> can be found on the ich homepage:http://www.ich.org/cache/compo/276-254-1.html. 4. guidelines on active pharmaceutical ingredient master ﬁ le procedure. in: who expert committee on speciﬁ cations for pharmaceutical preparations. forty-second <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>. geneva, world health organization, 2008, annex 4 (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, no. 948). 5.who guidelines for stability evaluation of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4635"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4636">vaccines</a></span></a></span>. in:who expert committee on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span> standardization.fifty-seventh <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>. geneva, world health organization (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, (in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2599">press</a></span>)) 
(http://www.who.int/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biologicals</a></span>/publications/trs/areas/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4635"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4636">vaccines</a></span></a></span>/stability/en/
index.html). 6. schumacher p. 1972. über eine für die haltbarkeit von arzneimitteln maßgebliche klimaeinteilung [the impact of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climate</a></span> classiﬁ cation on the stability of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1852">medicines</a></span>]. die pharmazeutische industrie, 34:481–483. 7. grimm w. 1986. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> (part 2). drugs made in germany, 29:39–47. 8. grimm w. 1998. extension of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation tripartite guidelines for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> to countries of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zones</a></span> iii and iv. drug development and industrial pharmacy, 24:313-325. 9. zahn m. et al. 2006. a risk-based approach to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditions for tropical countries. journal of pharmaceutical sciences,95:946–965. erratum: journal of pharmaceutical sciences, 2007, 96:2177.10. guidelines for registration of ﬁ xed-dose combination <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1852">medicinal</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. appendix 3: pharmaceutical development (or preformulation) studies. 
table a1: typical stress conditions in preformulation stability studies. in: 
who expert committee on speciﬁ cations for pharmaceutical preparations. 
thirty-ninth <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>. geneva, world health organization, 2005, annex 5 (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, no. 929).11.supplementary guidelines on good manufacturing practices: validation. in:quality assurance of pharmaceuticals. a compendium of guidelines and related materials. volume 2,2nd updated edition. good manufacturing practices and inspection. geneva, world health organization, 2007, chapter 1.11612. who good manufacturing practices: main principles for pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. in: quality assurance of pharmaceuticals. a compendium of guidelines and related materials. volume 2,2nd updated edition. good manufacturing practices and inspection. geneva, world health organization, 2007, chapter 1.13. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> on variations to a prequaliﬁ ed <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> dossier. in: who expert committee on speciﬁ cations for pharmaceutical preparations. forty-ﬁ rst 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>. geneva, world health organization, 2007, annex 6 (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, no. 943).14.prequaliﬁ cation programme – priority essential <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1852">medicines</a></span>. a united <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2033"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2034"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3521">nations</a></span></a></span></a></span> programme <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1154"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5081"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5281">managed</a></span></a></span></a></span> by who. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> for applicants
(http://mednet3.who.int/prequal/).15.<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1838">asean</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> on stability study of drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, 9th accsq-ppwg meeting, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2368">philippines</a></span>, 21–24 february 2005, version 22 february 2005. additional readingaccelerated stability studies of widely used pharmaceutical substances under <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6267">simulated</a></span> tropical conditions. geneva, world health organization, 1986 (who/pharm/86.529).117 appendix 1 long-term stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditions as identiﬁ ed by who member <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states1in</a></span> order to be able to reduce the amount of stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> required, the number of different long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditions must be reduced to a sufﬁ cient extent. this approach was proposed by paul schumacher in 1972(1) and by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8444">wolfgang</a></span> grimm in 1986(2), and in 1998(3) when they deﬁ ned four different long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditions, which match with the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> conditions of the target <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">markets</a></span></a></span> categorized in just four different 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zones</a></span>. this concept is described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> guidelines and 
pharmacopoeias and has become an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standard</a></span> in developing 
ﬁ nished pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (fpps).at the fortieth meeting of the who expert committee on speciﬁ cations for pharmaceutical preparations held in geneva in october 2005(4), it was <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> to split the current <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zone</a></span> iv (hot and humid) into 
two zones: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zone</a></span> iva – for which 30 °c/65% rh will remain the 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standard</a></span> long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> condition – and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zone</a></span> ivb for which, if 
justiﬁ ed, 30 °c/75% rh will become the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> condition. the criteriaand long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditions proposed are listed in table 1.table 1proposed criteriaand long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditionsclimaticzonedeﬁ nitioncriteriamean annual temperature 
measured in the open air/
mean annual partial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> 
vapour pressurelong-termtesting conditionsitemperateclimate 15 °c /  11 hpa21 °c / 45% rhiisubtropical and mediterranean
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climate</a></span>> 15 to 22 °c / > 11 to 18 hpa25 °c / 60% rhiiihot and dryclimate> 22 °c / 15 hpa30 °c / 35% rhivahot and humidclimate> 22 °c / > 15 to 27 hpa30 °c / 65% rhivbhot and very humid <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climate</a></span>> 22 °c / > 27 hpa30 °c / 75% rh1 any corrections or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1558">amendments</a></span> should be addressed to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1852">medicines</a></span> quality assurance programme, essential <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1852">medicines</a></span> and pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2440">policies</a></span>, world health organization, 
avenue appia, ch-1211 geneva 27, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4324">switzerland</a></span>, for the attention of dr s. kopp.118additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditions, i.e. accelerated and – if applicable – intermediate conditions have to be used as described in these guidelines.selection of the conditions for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> is based on a risk analysis. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at a more severe long-term condition can be an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at 25 °c/60% rh or 30 °c/65% rh.the evaluation of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> conditions by each who member <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">state</a></span> resulted in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition for long-term stability studies 
shown in table 2 (in some of the countries listed, more <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extreme</a></span> conditions 
are also accepted). the list is grouped by who <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regional</a></span></a></span> ofﬁ ces.table 2stability conditions for who member <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span> by regionmember statestability conditionsconﬁ rmed long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditionregional ofﬁ ce for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/281">africa</a></span> (afro)<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1196">algeria</a></span>[25 °c/60% rh]3angola[30 °c/65% rh]3benin[30 °c/65% rh]3botswana[25 °c/60% rh]3burkina faso30 °c/60% rh2burundi[30 °c/65% rh]3cameroon30 °c/75% rh2cape verde[30 °c/65% rh]3central <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/281">african</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3413">republic30</a></span> °c/75% rh2chad[30 °c/65% rh]3comoros[30 °c/65% rh]3congo[30 °c/65% rh]3côte d’ivoire[30 °c/65% rh]3democratic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3413">republic</a></span> of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/111">congo</a></span>[30 °c/65% rh]3equatorial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1216">guinea</a></span>[30 °c/65% rh]3eritrea[30 °c/65% rh]3ethiopia[30 °c/65% rh]3gabon[30 °c/65% rh]3gambia30 °c/65% rh1ghana30 °c/75% rh2guinea[30 °c/65% rh]3guinea-bissau[30 °c/65% rh]3kenya[30 °c/65% rh]3lesotho30 °c/75% rh2liberia[30 °c/65% rh]3madagascar30 °c/65% rh1malawi25 °c/60% rh2mali[30 °c/65% rh]3119member statestability conditionsconﬁ rmed long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditionmauritania[30 °c/65% rh]3mauritius[30 °c/65% rh]3mozambique30 °c/75% rh2namibia30 °c/65% rh1niger[30 °c/65% rh]3nigeria30 °c/75% rh2rwanda[30 °c/65% rh]3sao tome and principe30 °c/75% rh2senegal[30 °c/65% rh]3seychelles[30 °c/65% rh]3sierra leone30 °c/75% rh2south <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/281">africa30</a></span> °c/65% rh1swaziland[25 °c/60% rh]3togo30 °c/75% rh2uganda30 °c/65% rh1united <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3413">republic</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4376">tanzania30</a></span> °c/75% rh2zambia25 °c/60% or 30 °c/65% rh1zimbabwe30 °c/75% rh2regional ofﬁ ce for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1587">americas</a></span> (amro)<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3401">antigua and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4819">barbuda</a></span></a></span>[30 °c/75% rh]3argentina25 °c/60% rh2bahamas[30 °c/65% rh]3barbados30 °c/75% rh2belize[30 °c/65% rh]3bolivia[30 °c/70% rh or 30 °c/75% rh]3brazil30 °c/75% rh1canada30 °c/65% rh1chile30 °c/65% rh2colombia[30 °c/75% rh]3costa rica30 °c/65% rh2cuba30 °c/75% rh2dominica[30 °c/65% rh]3dominican <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3413">republic</a></span>[30 °c/65% rh]3ecuador[30 °c/65% rh]3el salvador[30 °c/65% rh]3grenada[30 °c/65% rh]3guatemala[30 °c/65% rh]3guyana[30 °c/70% rh or30 °c/75% rh]3haiti[30 °c/65% rh]3honduras[30 °c/65% rh]3jamaica[30 °c/65% rh]3mexico[25 °c/60% rh]3120member statestability conditionsconﬁ rmed long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditionnicaragua[30 °c/65% rh]3panama[30 °c/75% rh]3paraguay[30 °c/65% rh]3peru30 °c/75% rh1saint kitts and nevis[30 °c/65% rh]3saint lucia30 °c/75% rh2saint vincent and the grenadines[30 °c/75% rh]3suriname[30 °c/70% rh or30 °c/75% rh]3trinidad and tobago[30 °c/65% rh]3united <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1587">america25</a></span> °c/60% or 30 °c/65% rh1uruguay[25 °c/60% rh]3venezuela (bolivarian <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3413">republic</a></span> of)[30 °c/70% rh or30 °c/75% rh]3regional ofﬁ ce for the eastern mediterranean (emro)<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/261">afghanistan30</a></span> °c/65% rh1bahrain30 °c/65% rh1djibouti30 °c/65% rh1egypt30 °c/65% rh1iran (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1508">islamic</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3413">republic</a></span> of)30 °c/65% rh1iraq30 °c/35% rh1jordan30 °c/65% rh1kuwait30 °c/65% rh1lebanon25 °c/60% rh1libyan arab jamahiriya25 °c/60% rh1morocco25 °c/60% rh1oman30 °c/65% rh1pakistan30 °c/65% rh1qatar30 °c/65% rh1saudi arabia30 °c/65% rh1somalia30 °c/65% rh1sudan30 °c/65% rh1syrian arab <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3413">republic25</a></span> °c/60% rh1tunisia25 °c/60% rh1united arab emirates30 °c/65% rh1yemen30 °c/65% rh1regional ofﬁ ce for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/665"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/909"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4054">europe</a></span></a></span></a></span> (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/665"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4054">euro</a></span></a></span>)<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1125"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8499">albania</a></span></a></span>[25 °c/60% rh]3andorra[25 °c/60% rh]3armenia[25 °c/60% rh]3austria25 °c/60% or 30 °c/65% rh1azerbaijan30 °c/65% rh2121member statestability conditionsconﬁ rmed long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditionbelarus[25 °c/60% rh]3belgium25 °c/60% or 30 °c/65% rh1bosnia and herzegovina[25 °c/60% rh]3bulgaria25 °c/60% or 30 °c/65% rh1croatia[25 °c/60% rh]3cyprus25 °c/60% or 30 °c/65% rh1czech <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3413">republic25</a></span> °c/60% or 30 °c/65% rh1denmark25 °c/60% or 30 °c/65% rh1estonia25 °c/60% or 30 °c/65% rh1finland25 °c/60% or 30 °c/65% rh1france25 °c/60% or 30 °c/65% rh1georgia[25 °c/60% rh]3germany25 °c/60% or 30 °c/65% rh1greece25 °c/60% or 30 °c/65% rh1hungary25 °c/60% or 30 °c/65% rh1iceland[25 °c/60% rh]3ireland25 °c/60% or 30 °c/65% rh1israel30 °c/70% or 30 °c/75% rh2italy25 °c/60% or 30 °c/65% rh1kazakhstan[25 °c/60% rh]3kyrgyzstan[25 °c/60% rh]3latvia25 °c/60% or 30 °c/65% rh1lithuania25 °c/60% or 30 °c/65% rh1luxembourg25 °c/60% or 30 °c/65% rh1malta25 °c/60% or 30 °c/65% rh1monaco25 °c/60% or 30 °c/65% rh2montenegro[25 °c/60% rh]3netherlands25 °c/60% or 30 °c/65% rh1norway[25 °c/60% rh]3poland25 °c/60% or 30 °c/65% rh1portugal25 °c/60% or 30 °c/65% rh1republic of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5858">moldova</a></span>[25 °c/60% rh]3romania25 °c/60% or 30 °c/65% rh1russian <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3042">federation</a></span>[25 °c/60% rh]3san marino[25 °c/60% rh]3serbia [25 °c/60% rh]3slovakia25 °c/60% or 30 °c/65% rh1slovenia25 °c/60% or 30 °c/65% rh1spain25 °c/60% or 30 °c/65% rh1sweden25 °c/60% or 30 °c/65% rh1switzerland25 °c/60% or 30 °c/65% rh1122member statestability conditionsconﬁ rmed long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditiontajikistan[25 °c/60% rh]3the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">former</a></span> yugoslav <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3413">republic</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1717">macedonia25</a></span> °c/60% or 30 °c/65% rh2turkey[25 °c/60% rh]3turkmenistan[25 °c/60% rh]3ukraine[25 °c/60% rh]3united kingdom25 °c/60% or 30 °c/65% rh1uzbekistan[25 °c/60% rh]3regional ofﬁ ce for south-east <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2838">asia</a></span> (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1870">searo</a></span>)<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4732">bangladesh</a></span>[30 °c/65% rh]3bhutan30 °c/65% rh2democratic people’s <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3413">republic</a></span> of korea[25 °c/60% rh]3india30 °c/70% rh1indonesia30 °c/75% rh1maldives[30 °c/65% rh]3myanmar30 °c/75% rh1nepal30 °c/75% rh2sri lanka[30 °c/65% rh]3thailand30 °c/75% rh1timor-leste[30 °c/65% rh]3regional ofﬁ ce for the western paciﬁ c (wpro)<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4160">australia25</a></span> °c/60% or 30 °c/65% rh2brunei darussalam30 °c/75% rh1cambodia30 °c/75% rh1china[30 °c/65% rh]3cook <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1287">islands</a></span>[30 °c/65% rh]3fiji[30 °c/65% rh]3japan25 °c/60% or 30 °c/65% rh1kiribati[30 °c/65% rh]3lao people’s democratic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3413">republic30</a></span> °c/75% rh1malaysia30 °c/75% rh1marshall <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1287">islands</a></span>[30 °c/65% rh]3micronesia (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3042">federated</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span> of)[30 °c/65% rh]3mongolia[25 °c/60% rh]3nauru[30 °c/65% rh]3new zealand25 °c/60% or 30 °c/65% rh2niue[30 °c/65% rh]3palau[30 °c/65% rh]3papua new <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1216">guinea</a></span>[30 °c/65% rh]3philippines30 °c/75% rh1republic of korea25 °c/60% or 30 °c/65% rh2123member statestability conditionsconﬁ rmed long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditionsamoa[30 °c/65% rh]3singapore30 °c/75% rh1solomon <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1287">islands</a></span>[30 °c/65% rh]3tonga[30 °c/65% rh]3tuvalu[30 °c/65% rh]3vanuatu[30 °c/65% rh]3viet nam30 °c/75% rh11information obtained through respective <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regional</a></span></a></span> harmonization groups (e.g. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1838">asean</a></span>, ich and gcc) and from ofﬁ cial communications from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2033"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2034"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3521">national</a></span></a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1852">medicines</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> authorities to who (entries in bold type).2information collated during the 13th <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> of drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> authorities (icdra), 16–18 
september 2008, held in bern, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4324">switzerland</a></span>, from representatives of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2033"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2034"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3521">national</a></span></a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1852">medicines</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> authorities 
(entries in normal type).3information provided by the international <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3042">federation</a></span> of pharmaceutical manufacturers and associations 
(ifpma) [entries in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1519">italic</a></span> type] based on the following references:
ahrens cd. 2001. essentials of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1892">meteorology</a></span> 3rd ed. belmont, ca, thomson books/cole, p. 433.kottek m, et al.2006. world map of köppen-geiger <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climate</a></span> classiﬁ cation updated. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1892">meteorologische</a></span> zeitschrift,15:259–263.
zahn m. et al. 2006. a risk-based approach to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditions for tropical countries. journal of pharmaceutical sciences, 95:946–965. erratum journal of pharmaceutical sciences, 2007, 96:2177.zahn m. 2008. global stability practices. in: huynh-ba, kim ed. handbook of stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> in pharmaceutical development, new york, springer.references 1. schumacher p. 1972, über eine für die haltbarkeit von arzneimitteln maßgebliche klimaeinteilung [the impact of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climate</a></span> classiﬁ cation on the 
stability of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1852">medicines</a></span>]. die pharmazeutische industrie, 34:481–483. 2. grimm w. 1986, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> (part 2). drugs made in germany, 29:39–47. 3. grimm w. 1998. extension of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation tripartite guidelines for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 
to countries of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4786"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6011">climatic</a></span> zones</a></span> iii and iv. drug development and industrial pharmacy, 24:313-325. 4. guidelines for stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containing</a></span> well <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> drug substances in conventional dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span>. in: who expert committee on speciﬁ cations for pharmaceutical preparations. thirty-fourth 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>. geneva, world health organization, 1996, annex 5 (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, no. 863). these guidelines were revised at the thirty-seventh and fortieth meetings of the who expert committee on speciﬁ cations for pharmaceutical 
preparations. in: who expert committee on speciﬁ cations for pharmaceutical preparations. thirty-seventh <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>. geneva, world health organization, 2003 (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, no. 908), p. 13 and whoexpert committee on speciﬁ cations for pharmaceutical preparations. fortieth 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>. geneva, world health organization, 2006 (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, no. 937, p. 12.124 appendix 2 examples of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> parameters <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> i for active pharmaceutical ingredientsin general, appearance, assay and degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should be evaluated for all active pharmaceutical ingredients (apis). other api parameters that 
may be susceptible to change should also be studied where applicable. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> ii for ﬁ nished pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">productsthe</a></span></a></span> following list of parameters for each dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> is presented as a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guide</a></span> to the types of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> to be included in a stability study. in general, appearance, 
assay and degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should be evaluated for all dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span>, as 
well as the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> and antioxidant content if applicable.the microbial quality of multiple-dose sterile and non-sterile dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> should be controlled. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8458">challenge</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> should be carried out at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> at the 
beginning and at the end of the shelf-life. such <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> would normally be 
performed as part of the development programme, for example, within 
primary stability studies. they need not be repeated for subsequent stability 
studies unless a change has been made which has a potential impact on 
microbiological status.it is not expected that every <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> listed be performed at each time point. this applies in particular to sterility <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>, which may be conducted for most 
sterile <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> at the beginning and at the end of the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> period. 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> for pyrogens and bacterial endotoxins may be limited to the time of 
release. sterile dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containing</a></span> dry materials (powder ﬁ lled or lyophilized <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>) and solutions <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1870"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6406">sealed</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4676">glass</a></span> ampoules 
may need no additional microbiological <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> beyond the initial time 
point. the level of microbiological contamination in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1672">liquids</a></span> packed in 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4676">glass</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> with ﬂ exible <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1870"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6406">seals</a></span></a></span> or in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1837">plastic</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> no less than at the beginning and at the end of the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> 
period; if the long-term data provided to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> authorities for 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span> authorization registration do not cover the full shelf-life period, 
the level of microbial contamination at the last time point should also be 
provided.the list of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> presented for each dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> is not intended to be exhaustive, nor is it expected that every <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> listed be included in the design 
of a stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> for a particular ﬁ nished pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> (fpp) (for example, a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> for odour should be performed only when necessary 
and with consideration for the analyst’s safety).125the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> orientation of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, i.e. upright versus inverted, may need to be included in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> when contact of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> with the closure 
system may be expected to affect the stability of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contained</a></span>, or 
where there has been a change in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system.tabletsdissolution (or disintegration, if justiﬁ ed), <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> content and hardness/friability.capsuleshard <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6787">gelatin</a></span> capsules: brittleness, dissolution (or disintegration, if •justiﬁ ed), <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> content and level of microbial contamination.soft <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6787">gelatin</a></span> capsules: dissolution (or disintegration, if justiﬁ ed), level of •microbial contamination, ph, leakage, and pellicle <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formation</a></span>.oral solutions, suspensions and emulsionsformation of precipitate, clarity (for solutions), ph, viscosity, extractables, 
level of microbial contamination.additionally for suspensions, dispersibility, rheological properties, mean size and distribution of particles should be considered. also polymorphic 
conversion may be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/925">examined</a></span>, if applicable.additionally for emulsions, phase separation, mean size and distribution of dispersed globules should be evaluated.powders and granules for oral solution or suspensionwater content and reconstitution time.reconstituted <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (solutions and suspensions) should be evaluated as described above under “oral solutions suspensions and emulsions”, after 
preparation according to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span>, through the maximum 
intended use period.metered-dose inhalers and nasal <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/212">aerosolsdose</a></span> content uniformity, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelled</a></span> number of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3813">medication</a></span> actuations per 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> meeting dose content uniformity, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4107">aerodynamic</a></span> particle size 
distribution, microscopic evaluation, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> content, leak rate, level of 
microbial contamination, valve delivery (shot weight), extractables/
leachables from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1837">plastic</a></span> and elastomeric components,weight <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3851">pump</a></span> delivery, foreign particulate matter and extractables/leachables from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1837">plastic</a></span> 
and elastomeric components of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span>, closure and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3851">pump</a></span>. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> 
should be stored in upright and inverted/on-the-side orientations.for suspension-type <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/212">aerosols</a></span>, microscopic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/925">examination</a></span> of appearance of the valve components and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span>’s contents for large particles, changes 
in morphology of the api particles, extent of agglomerates, crystal growth, 126foreign particulate matter, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/243">corrosion</a></span> of the inside of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> or deterioration of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1139">gaskets</a></span>.nasal sprays: solutions and suspensionsclarity (for solution), level of microbial contamination, ph, particulate 
matter, unit spray <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3813">medication</a></span> content uniformity, number of actuations 
meeting unit spray content uniformity per <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span>, droplet and/
or particle size distribution, weight <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3851">pump</a></span> delivery, microscopic 
evaluation (for suspensions), foreign particulate matter and extractables/
leachables from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1837">plastic</a></span> and elastomeric components of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span>, 
closure and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3851">pump</a></span>.topical, ophthalmic and otic preparationsincluded in this broad category are ointments, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/301">creams</a></span>, lotions, paste, gel, 
solutions, eye drops and cutaneous sprays.topical preparations should be evaluated for clarity, homogeneity, ph, •suspendability (for lotions), consistency, viscosity, particle size distribution 
(for suspensions, when feasible), level of microbial contamination/sterility 
and weight <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> (when appropriate).evaluation of ophthalmic or otic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (e.g. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/301">creams</a></span>, ointments, •solutions and suspensions) should include the following additional 
attributes: sterility, particulate matter and extractable volume.
evaluation of cutaneous sprays should include: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2599">pressure</a></span>, weight <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span>, net •weight dispensed, delivery rate, level of microbial contamination, spray 
pattern, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> content and particle size distribution (for suspensions).suppositoriessoftening range, disintegration and dissolution (at 37 °c).small volume parenterals (svps)colour, clarity (for solutions), particulate matter, ph, sterility, endotoxins.stability studies for powders for injection solution should include monitoring for colour, reconstitution time and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> content. speciﬁ c parameters to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/925">examined</a></span> at appropriate intervals throughout the maximum intended 
use period of the reconstituted drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, stored under condition(s) 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span>, should include clarity, colour, ph, sterility, 
pyrogen/endotoxin and particulate matter.it may be appropriate to consider 
monitoring of sterility after reconstitution into a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, e.g. dual-chamber 
syringe, where it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5559">claimed</a></span> that reconstitution can be performed without 
compromising sterility.the stability studies for suspension for injection should include, in addition, •particle size distribution, dispersibility and rheological properties.127the stability studies for emulsion for injection should include, in addition, •phase separation, viscosity, mean size and distribution of dispersed phase 
globules.large volume parenterals (lvps)colour, clarity, particulate matter, ph, sterility, pyrogen/endotoxin and 
volume.transdermal patchesin vitro release rates, leakage, level of microbial contamination/sterility, 
peel and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3">adhesive</a></span> forces.128appendix 3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> statements1. active pharmaceutical ingredientsthe <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> that should be used if supported by the stability studies for active pharmaceutical ingredients (apis) are listed in table 1.table 1recommended <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> for active pharmaceutical ingredients (apis)<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> condition under which the stability of the api has been demonstratedrecommended labellingstatementa25 °c/60% rh (long-term)
40 °c/75% rh (accelerated)“do not store above 25 °c” 25 °c/60% rh (long-term)30 °c/65% rh (intermediate, failure of accelerated)“do not store above 25 °c”b30 °c/65% rh (long-term)40 °c/75% rh (accelerated)“do not store above 30 °c”b30 °c/75% rh (long-term)40 °c/75% rh (accelerated)“do not store above 30 °c”5 °c ± 3 °c”store in a refrigerator(2 °c to 8 °c)” -20 °c ± 5 °c“store in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>” a during <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span>, shipment and distribution of the api, the current good trade and distribution practices (gtdp) for pharmaceutical starting materials are to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span>(1). details on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> requirements can be found in who <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guide</a></span> to good <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> practices for pharmaceuticals (2).b “protect from moisture” should be added as applicable.2. finished pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">productsthe</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> that should be used if supported by the stability studies for ﬁ nished pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (fpps) are listed in table 2.129table 2recommended <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> for ﬁ nished pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (fpps)<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> condition under which the stability of the fpp has been demonstratedrecommended labellingstatementa25 °c/60% rh (long-term)
40 °c/75% rh (accelerated)“do not store above 25 °c” 25 °c/60% rh (long-term)30 °c/65% rh (intermediate, failure of accelerated)“do not store above 25 °c”b30 °c/65% rh (long-term)40 °c/75% rh (accelerated)“do not store above 30 °c” b 30 °c/75% rh (long-term)40 °c/75% rh (accelerated)“do not store above 30 °c”5 °c ± 3 °c”store in a refrigerator(2 °c to 8 °c)” -20 °c ± 5 °c“store in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>” a during <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span>, shipment and distribution of the fpp, the current good distribution practices (gdp) for pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> are to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> (3). details on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> requirements can be found inwho <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guide</a></span> to good <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> practices for pharmaceuticals (2).b  “protect from moisture” should be added as applicable.in principle, fpps should be packed in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> that ensure stability and protect the fpp from deterioration. a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span> should not be used 
to compensate for inadequate or inferior <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span>. additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> that could be used in cases where the result of the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> 
demonstrates limiting factors are listed in table 3.table 3additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> for use where the result of the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> demonstrates limiting factorslimiting factorsadditional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labelling</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span>, where relevantfpps that cannot tolerate refrigeration“do not refrigerate or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freeze</a></span>”afpps that cannot tolerate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezing</a></span>“do not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freeze</a></span>”alight-sensitive fpps“protect from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>”
fpps that cannot tolerate excessive <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5503">heat</a></span>, e.g. suppositories“store and transport not above 30 °c”hygroscopic fpps “store in dry condition”a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depending</a></span> on the pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> and the properties of the fpp, there may be a risk of deterioration due to physical changes if subjected to low temperatures, e.g. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1672">liquids</a></span> and semi-solids. low temperatures may also 
have an effect on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> in certain cases. an additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span> may be necessary to take <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> 
of this possibility.130references1. good trade and distribution practices for pharmaceutical starting materials. in: who expert committee on speciﬁ cations for pharmaceutical preparations. thirty-eighth <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>. geneva, world health organization, 2004, annex 2 (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, no. 917) (http://whqlibdoc.who.int/
trs/who_trs_917_annex2.pdf).2. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guide</a></span> to good <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> practices for pharmaceuticals. in: who expert committee on speciﬁ cations for pharmaceutical preparations. thirty-seventh <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>. geneva, world health organization, 2003, annex 9 (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> series, no. 908).3. good distribution practices for pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. in: who expert committee on speciﬁ cations for pharmaceutical preparations. fortieth <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span>.geneva, world health organization, 2006, annex 5 (who technical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> 
series, no. 937). currently under revision (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> qas/08.252).</body><html>